Strengthening Families & Communities LLC Raises Stock Position in Merck & Co., Inc. $MRK

Strengthening Families & Communities LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 12.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,767 shares of the company’s stock after buying an additional 5,125 shares during the quarter. Merck & Co., Inc. comprises about 1.8% of Strengthening Families & Communities LLC’s holdings, making the stock its 15th biggest holding. Strengthening Families & Communities LLC’s holdings in Merck & Co., Inc. were worth $5,028,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Westside Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 3.1% during the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after buying an additional 93 shares during the last quarter. Valued Wealth Advisors LLC lifted its position in shares of Merck & Co., Inc. by 26.9% during the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock worth $47,000 after buying an additional 94 shares during the last quarter. Payne Capital LLC lifted its position in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Payne Capital LLC now owns 10,637 shares of the company’s stock worth $1,120,000 after buying an additional 97 shares during the last quarter. Abound Wealth Management lifted its position in shares of Merck & Co., Inc. by 6.8% during the 4th quarter. Abound Wealth Management now owns 1,554 shares of the company’s stock worth $164,000 after buying an additional 99 shares during the last quarter. Finally, ST Germain D J Co. Inc. lifted its position in shares of Merck & Co., Inc. by 0.3% during the 4th quarter. ST Germain D J Co. Inc. now owns 38,645 shares of the company’s stock worth $4,068,000 after buying an additional 99 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 1.2%

MRK stock opened at $112.22 on Friday. The company has a fifty day moving average price of $117.07 and a 200 day moving average price of $108.31. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The company has a market cap of $277.17 billion, a price-to-earnings ratio of 31.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the firm earned $2.22 EPS. Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Analyst Ratings Changes

MRK has been the subject of several recent analyst reports. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday. They set a “neutral” rating and a $125.00 price objective for the company. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. UBS Group upped their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Cantor Fitzgerald upped their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Finally, Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target for the company in a research report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a Science paper describing a scalable, enzyme-driven synthesis for its investigational oral PCSK9 inhibitor enlicitide decanoate — a notable R&D milestone that supports the commercial potential of a new oral lipid-lowering modality. Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
• Positive Sentiment: Merck’s BioReliance unit inked a five‑year deal to be the sole testing provider for Genetix Biotherapeutics’ FDA‑approved gene therapies — adds recurring, commercial‑stage service revenue and reinforces Merck’s role in cell & gene therapy commercialization. Merck Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
• Positive Sentiment: Merck completed the Terns acquisition to expand its chronic myeloid leukemia (CML) pipeline; the deal and FDA breakthrough designation for a TERN asset strengthen oncology pipeline optionality. MSD concludes Terns acquisition to expand CML pipeline
• Positive Sentiment: Analysts and brokers showed support after Merck’s Q1 beat — one analyst nudged the price target higher and BMO reiterated a buy — giving near‑term fundamental backing to the stock. Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates BMO Capital Remains a Buy on Merck & Company (MRK)
• Neutral Sentiment: Merck Animal Health selected Salesforce’s Agentforce Life Sciences for omnichannel engagement — a strategic IT/customer‑engagement win but with modest near‑term financial impact versus drug/cell‑therapy drivers. Salesforce AI Win With Merck Highlights Real World Platform Adoption
• Neutral Sentiment: Citigroup initiated coverage with a “neutral” rating and a $125 price target — supportive of upside but not a strong buy signal; highlights mixed analyst views on valuation vs. growth. Citigroup Initiates Coverage
• Negative Sentiment: Sector competitors posted robust oncology and diabetes results (J&J oncology growth; Eli Lilly’s blockbuster Mounjaro sales), underscoring competitive pressure in key therapeutic areas and possibly contributing to profit‑taking and relative valuation compression for Merck. Sector Competitive Moves Darzalex, Erleada & New Drugs Keep J&J’s Oncology Engine Charged in Q1 Eli Lilly Now Has the World’s Best-Selling Drug — But Does That Make the Stock a No-Brainer Buy?

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the transaction, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares in the company, valued at $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.17% of the stock is owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.